Evaluation and management of men whose radical prostatectomies failed: Results of an international survey

Urology

Volumn 52, Issue 6, 1998, Pages 1047-1054

  Ornstein, David K ^a   Colberg, John W ^a   Virgo, Katherine S ^b,c   Chan, Danny ^b   Johnson, Eric T ^c   Oh, Joseph ^a   Johnson, Frank E ^b,c  

^a WASHINGTON UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

ADULT; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROFESSIONAL PRACTICE; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUESTIONNAIRES; TREATMENT FAILURE; UROLOGY;

EID: 0032402182     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00403-8     Document Type: Article

References (25)

1. Newcomer L.M., Stanford J.L., Blumenstein B.A., et al. Temporal trends in rates of prostate cancer declining incidence of advanced stage disease, 1974 to 1994 . J Urol. 158:1997;1427-1430.
2. Andriole G.L., Smith D.S., Rao G., et al. Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol. 152:1994;1858-1860.
3. Gerber G.S., Thisted R.A., Scardino P.T., et al. Results of radical prostatectomy in men with clinically localized prostate cancer multi-institutional pooled analysis . J Am Med Assoc. 276:1996;615-619.
4. Lu-Yao G.L., McLerran D., Wasson J., et al. An assessment of radical prostatectomy time trends, geographic variation, and outcomes - The Prostate Patient Outcomes Research Team . J Am Med Assoc. 269:1993;2633-2636.
5. Partin A.W., Pound C.R., Clemens J.Q. Serum PSA after radical prostatectomy. Urol Clin North Am. 20:1993;713-725.
6. Zincke H., Oesterling J.E., Blute M.L., et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 152:1994;1850-1857.
7. Frazier H.A., Robertson J.E., Humphrey P.A., et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol. 149:1993;516-518.
8. Lange P.H., Lightner D.J., Medini E., et al. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol. 144:1990;927-932.
9. Foster L.S., Jajodia P., Fournier G., et al. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrence following radical prostatectomy. J Urol. 149:1993;1024-1028.
10. Lightner D.J., Lange P.H., Reddy P.K., et al. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 144:1990;921-926.
11. Freitas J.E., Gilvydas R., Ferry J.D., et al. The clinical utility of prostate-specific scintigraphy in prostate cancer follow-up. J Nucl Med. 32:1991;1387-1390.
12. Connolly J.A., Shinohara K., Presti J.C., et al. Local recurrence after radical prostatectomy characteristics in size, location, and relationship to prostate-specific antigen and surgical margins . Urology. 47:1996;225-230.
13. Castellino R.A. Retroperitoneal and pelvic lymph node imaging. Cancer. 67:1991;1219-1222.
14. Mukamel E., Hannah J., Barbaric Z., et al. The value of computed tomography scan and magnetic resonance imaging in staging prostatic carcinoma comparison with clinical and histological staging . J Urol. 136:1986;1231-1233.
15. 111Indium-labeled monoclonal antibody CYT-356. J Urol. 152:1994;1952-1955.
16. Burgers J.K., Hinkle G.H., Haseman M. Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol. 13:1995;103-112.
17. Haseman M.K., Reed N.L., Rosenthal S.A. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen, positron emission tomography and biopsy correlation. Clin Nucl Med. 21:1996;704-713.
18. Schild S.E., Wong W.W., Grado G.L., et al. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc. 69:1994;613-619.
19. Cadeddu J.A., Partin A.W., DeWeese T.L., et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 159:1998;173-178.
20. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy, patterns of recurrence and cancer control. Urol Clin North Am. 24:1997;395-406.
21. Byar D.P. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 32:1973;1126-1130.
22. Immediate versus deferred treatment for advanced prostatic cancer initial results of the Medical Research Council Trial . Br J Urol. 79:1997;235-245.
23. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
24. Caubet J.F., Tosteson T.D., Dong E.W., et al. Maximum androgen blockade in advanced prostate cancer a meta-analysis of published randomized controlled trials using non-steroidal antiandrogens . Urology. 49:1997;71-78.
25. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate (CaP) results of NCI intergroup study 0105 (SWOG and ECOG) . J Urol. 157A:1997;336.